ストックスクリーナーアプリを入手
9.21
15.13%
1.21
アフターアワーズ：
9.21
前日終値:
$8.00
開ける：
$9.83
24時間の取引高:
1,380
Relative Volume:
0.36
時価総額：
$N/A
収益：
-
当期純損益:
-
株価収益率:
-
EPS:
-
ネットキャッシュフロー:
-
1週間 パフォーマンス:
+15.13%
1か月 パフォーマンス:
+4.90%
6か月 パフォーマンス:
-37.69%
1年 パフォーマンス:
-7.44%
1日の値動き範囲:
$8.49
$9.83
1週間の範囲:
$8.49
$9.83
52週間の値動き範囲:
$5.45
$16.75
Newamsterdam Pharma Company N V Stock (NAMSW) Company Profile
名前
Newamsterdam Pharma Company N V
セクター
電話
31 35 206 2971
住所
Gooimeer 2-35, Naarden
NAMSW を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
NAMSW
Newamsterdam Pharma Company N V
|
9.21 | 0 | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
459.41 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
538.11 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
324.13 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
546.04 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
240.99 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Newamsterdam Pharma Company N V (NAMSW) 最新ニュース
NewAmsterdam Pharma (NASDAQ:NAMS) Now Covered by Citigroup - Defense World
Citi initiates NewAmsterdam Pharma stock with buy rating on cholesterol drug - Investing.com Nigeria
Citi Recommends NewAmsterdam Pharma (NAMS) with a Strong Outlook | NAMS Stock News - GuruFocus
How the (NAMS) price action is used to our Advantage - news.stocktradersdaily.com
Stifel initiates NewAmsterdam stock with Buy rating, $44 target By Investing.com - Investing.com Nigeria
NewAmsterdam Pharma’s SWOT analysis: stock poised for cardiovascular breakthrough By Investing.com - Investing.com South Africa
NewAmsterdam Pharma’s SWOT analysis: stock poised for cardiovascular breakthrough - Investing.com
NewAmsterdam Pharma’s (NAMS) “Buy” Rating Reaffirmed at Needham & Company LLC - Defense World
NAMS: Needham Reiterates Buy Rating and Maintains Price Target | - GuruFocus
Cantor Fitzgerald maintains NewAmsterdam Pharma stock rating on trial data By Investing.com - Investing.com India
NewAmsterdam Pharma stock maintains buy rating at Stifel on strong data - Investing.com Nigeria
Cantor Fitzgerald maintains NewAmsterdam Pharma stock rating on trial data - Investing.com
California State Teachers Retirement System Raises Position in NewAmsterdam Pharma (NASDAQ:NAMS) - Defense World
13 Biotech Stocks with Huge Upside Potential - Insider Monkey
NewAmsterdam Pharma Company N.V. (NAMS) Initiated with a Buy at Stifel - Insider Monkey
Transcript : NewAmsterdam Pharma Company N.V.Special Call - MarketScreener
Frazier Lifesciences Acquisition : NewAmsterdam Pharma R&D Day 2025 - MarketScreener
NewAmsterdam Pharma Schedules R&D Day for June 2025 - TipRanks
Brokers Set Expectations for NAMS FY2026 Earnings - Defense World
NewAmsterdam Pharma (NASDAQ:NAMS) Coverage Initiated by Analysts at Stifel Nicolaus - Defense World
Kalkine: NewAmsterdam Pharma Progress in Nasdaq Index Spotlight Event - Kalkine Media
(NAMSW) Technical Pivots with Risk Controls - news.stocktradersdaily.com
NewAmsterdam Pharma (NAMS): Stifel Initiates Coverage with Buy Rating | NAMS Stock News - GuruFocus
NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Analysts Just Trimmed Their Revenue Forecasts By 14% - simplywall.st
Analysts Have Just Cut Their NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Revenue Estimates By 14% - Yahoo Finance
Stifel Nicolaus Initiates Coverage on NewAmsterdam Pharma With Buy Rating, $44 Price Target - marketscreener.com
Stifel Initiates Coverage on NewAmsterdam Pharma (NAMS) with Pos - GuruFocus
Stifel initiates NewAmsterdam stock with Buy rating, $44 target - Investing.com
NewAmsterdam Pharma (NAMS) Reveals Alzheimer's Biomarker Data fr - GuruFocus
Analyst Says NewAmsterdam Stock Has Over 100% Upside, Citing 90% Success Probability For Obicetrapib - Benzinga
NewAmsterdam Says Obicetrapib Shows 'Significant' Reduction in Alzheimer's Biomarker; Shares Rise - marketscreener.com
NewAmsterdam reports Alzheimer’s biomarker reduction - Investing.com
NewAmsterdam Pharma (NAMS) Reveals Alzheimer's Biomarker Data from Key Trial | NAMS Stock News - GuruFocus
NewAmsterdam Pharma Reveals Positive Topline Data From BROADWAY Clinical Trial - Nasdaq
NewAmsterdam reports Alzheimer’s biomarker reduction By Investing.com - Investing.com India
NewAmsterdam Pharma Announces Positive Topline Alzheimer’s Disease Data from BROADWAY Clinical Trial - GlobeNewswire
NewAmsterdam Pharma Company N.V. Announces Positive Topline Alzheimer's Disease Data from Br Broadway Clinical Trial - marketscreener.com
Bank of America Corp DE Grows Stock Position in NewAmsterdam Pharma (NASDAQ:NAMS) - Defense World
NewAmsterdam Pharma Approves Key Proposals at AGM - TipRanks
NewAmsterdam Pharma to Host R&D Day on June 11, 2025 - GlobeNewswire
NewAmsterdam Pharma (NASDAQ:NAMS) Now Covered by Cantor Fitzgerald - Defense World
NewAmsterdam Pharma R&D Day: Key Pipeline Updates Coming for Revolutionary Cardiovascular Treatments - Stock Titan
NewAmsterdam Pharma (NAMS) versus Its Rivals Head-To-Head Review - Defense World
NewAmsterdam Pharma (NAMS) Receives Overweight Rating from Canto - GuruFocus
Cantor Fitzgerald initiates overweight rating for NewAmsterdam Pharma stock - Investing.com
Cantor Fitzgerald initiates overweight rating for NewAmsterdam Pharma stock By Investing.com - Investing.com India
Cantor Fitzgerald Initiates NewAmsterdam Pharma Overweight With $42 Price Target - marketscreener.com
RBC Capital maintains outperform rating for NewAmsterdam Pharma stock By Investing.com - Investing.com Canada
RBC Capital maintains outperform rating for NewAmsterdam Pharma stock - Investing.com
Northern Trust Corp Takes $556,000 Position in NewAmsterdam Pharma (NASDAQ:NAMS) - Defense World
NewAmsterdam Pharma (NASDAQ:NAMS) Rating Increased to Hold at Wall Street Zen - Defense World
Newamsterdam Pharma Company N V (NAMSW) 財務データ
Newamsterdam Pharma Company N V (NAMSW) の財務データはありません。詳細については、他の銘柄を確認してください。
収益
当期純利益
現金流量
EPS
1.08%
2.14%
大文字化:
|
ボリューム (24 時間):